Yedid Elbez on Muck Rack

Yedid Elbez

As seen in: heart, Canadian Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yedid

Contact Yedid, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

|
By Chern-En Chiang, Gregory Schwartz, Yedid Elbez, Michael Szarek, Gregory Schwartz, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Andrejs Erglis, Shaun G. Goodman, Emil Hagstrom, J. Wouter Jukema, Evangelos N. Liberopoulos, Robert Pordy, Harvey D. White, Megan Loy
| Canadian Journal of Cardiology Verified
Article Info Publication History Accepted: May 22, 2022 Received in revised form: May 17, 2022 Received: May 4, 2022 Publication stage In Press Journal Pre-Proof Footnotes A limited set of these data was presented at the Annual Scientific Session of the American College of Cardiology, held in May 2021. FUNDING SUPPORT: Sanofi, Paris, France, and Regeneron Pharmaceuticals, Inc., Tarrytown, NJ, USA.
Open in Who Shared Issue with article?

EFFECTS OF ALIROCUMAB ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION: SUBANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL:

|
By Chern-En Chiang, Gregory Schwartz, Yedid Elbez, Deepak L. Bhatt
| jacc.org
JACC Journals › JACC › Archives › Vol. 77 No. 18_Supplement_1 Ischemic Heart Disease Multimedia References Related Details Information Copyright © 2021, The Author. Published by Elsevier on Behalf of The American College of Cardiology Foundation. This is an Open Access Article under the CC BY-NC-ND License (http://creativecommons.org/licenses/by-nc-nd/4.0/). Article History Published onlineMay 3, 2021
Open in Who Shared Issue with article?

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk

|
By Louis Potier, Ronan Roussel, Yedid Elbez, Hôpital Bichat
| heart Verified
The REACH registry provides an opportunity to directly compare ACEIs’ and ARBs’ effectiveness in routine clinical practice, in a contemporary large cohort of outpatients with high CV risk, with a variety of comorbidities, broad geographic representation and under well-defined intensity of preventive therapy.
Open in Who Shared Issue with article?
See all 4 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified